Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

The Beijing-based American Chamber of Commerce said on Friday that companies in the pharmaceutical sector had reported that ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Reckitt Benckiser's CEO, Kris Licht, highlighted India as a key growth driver, anticipating sustained strong volume growth ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Where thousands of former Health and Human Services employees will work next is unknown, but biopharma companies likely ...

EUDA Health Holdings Limited ('EUDA” or the 'Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, ...

As global trade tensions escalate, the United States may benefit from applying the concept of precision medicine to ...

Sakshi holds a BSc in Biotechnology from the University of Birmingham and an MBA from The Wharton School. She began her ...

Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and ...